Reply to Gan <i>et al.</i>, to Calzetta <i>et al.</i>, and to Poor-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Reply to Gan et al., to Calzetta et al., and to Poor

Published:2024-01-15 Issue:2 Volume:209 Page:226-228
ISSN:1073-449X
Container-title:American Journal of Respiratory and Critical Care Medicine
language:en
Short-container-title:Am J Respir Crit Care Med

Author:

Anzueto Antonio¹²,Barjaktarevic Igor Z.³,Siler Thomas M.⁴,Rheault Tara⁵,Bengtsson Thomas⁶,Rickard Kathleen⁵,Sciurba Frank⁷

Affiliation:

1. South Texas Veterans Health Care System, San Antonio, Texas;

2. University of Texas Health, San Antonio, Texas;

3. Division of Pulmonary and Critical Care, University of California Los Angeles, Los Angeles, California;

4. Midwest Chest Consultants, PC, St. Charles, Missouri;

5. Verona Pharma Plc, London, United Kingdom and Raleigh, North Carolina;

6. StatMind AB, Lund, Sweden; and

7. Division of Pulmonary and Critical Care Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania

Funder

Verona Pharma

Publisher

American Thoracic Society

Subject

Critical Care and Intensive Care Medicine,Pulmonary and Respiratory Medicine

Link

https://www.atsjournals.org/doi/pdf/10.1164/rccm.202309-1657LE

Reference14 articles.

1. Ensifentrine, a Novel Phosphodiesterase 3 and 4 Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease: Randomized, Double-Blind, Placebo-controlled, Multicenter Phase III Trials (the ENHANCE Trials)

2. Ensifentrine as a Novel, Inhaled Treatment for Patients with COPD

3. The Pharmacology of Two Novel Long-Acting Phosphodiesterase 3/4 Inhibitors, RPL554 [9,10-Dimethoxy-2(2,4,6-trimethylphenylimino)-3-(N-carbamoyl-2-aminoethyl)-3,4,6,7-tetrahydro-2H-pyrimido[6,1-a]isoquinolin-4-one] and RPL565 [6,7-Dihydro-2-(2,6-diisopropylphenoxy)-9,10-dimethoxy-4H-pyrimido[6,1-a]isoquinolin-4-one]

4. ANTIINFLAMMATORY PHARMACOLOGY OF ENSIFENTRINE

5. Efficacy and safety of RPL554, a dual PDE3 and PDE4 inhibitor, in healthy volunteers and in patients with asthma or chronic obstructive pulmonary disease: findings from four clinical trials

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3